A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

Analia Azaro, Christophe Massard, William D. Tap, Philippe A. Cassier, Jaime Merchan, Antoine Italiano, Bailey Anderson, Eunice Yuen, Danni Yu, Gerard Oakley, Karim A. Benhadji, Shubham Pant

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences